ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Diaceutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was 13.30%.
As of today (2026-06-30), Diaceutics's WACC % is 13.17%. Diaceutics's ROIC % is 0.04% (calculated using TTM income statement data).
Diaceutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Diaceutics (LSE:DXRX) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Diaceutics's WACC % is 13.17%. Diaceutics's ROIC % is 0.04% (calculated using TTM income statement data).
Diaceutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Diaceutics ROIC % Related Terms
Diaceutics ROIC % Historical Data
* Premium members only.
The historical data trend for Diaceutics's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diaceutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics ROIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's ROIC % distribution charts can be found below:
* The bar in red indicates where Diaceutics's ROIC % falls into.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (LSE:DXRX) has a ROIC % of 13.30% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Diaceutics and its competitors.
Is Diaceutics' ROIC % too high?
Diaceutics' current ROIC % is 13.30%. The Healthcare Providers & Services industry median ROIC % is 3.08. Diaceutics' value of 13.30% is 332.5% above this industry median. Overall, Diaceutics has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' ROIC % compare to VEEV and BTSG?
Diaceutics' ROIC % of 13.30% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROIC % is 3.08. Diaceutics' value of 13.30% is 332.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Healthcare Providers & Services company?
The median ROIC % among Healthcare Providers & Services companies is 3.08, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current ROIC % of 13.30% is 332.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median ROIC % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current ROIC % is 13.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (LSE:DXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is £1.91, compared to a current price of £1.45 — trading 24.3% below its estimated fair value. The current ROIC % is 13.30% and 332.5% above the Healthcare Providers & Services industry median of 3.08. Diaceutics' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Diaceutics (LSE:DXRX), the current ROIC % is 13.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (LSE:DXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of £1.45 is trading 24.3% below its estimated GF Value™ of £1.91.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for LSE:DXRX:
ROIC %: 13.30%
GF Value™: £1.91 vs. price of £1.45 (24.3% below fair value)
Industry Position: 332.5% above the Healthcare Providers & Services median
No single metric tells the full story. See the LSE:DXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
91GF Score
Get the complete analysis for LSE:DXRX
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:DXRX has been successfully added to your 
